EASL HCC summit: Liver cancer management

Future Oncology

Volumn 10, Issue 7, 2014, Pages 1129-1132

  Sacco, Rodolfo ^a   Gadaleta Caldarola, Gennaro ^b   Galati, Giovanni ^c   Lombardi, Giuseppe ^d   Mazza, Giancarlo ^e   Cabibbo, Giuseppe ^f  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b Istituto Oncologico di Bari   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e Private Practice   (Italy)

^f UNIVERSITY OF PALERMO   (Italy)

Author keywords

cost effectivness; disease management; HCC; locoregional treatments; sorafenib; TACE

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER SURGERY; CHEMOEMBOLIZATION; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; HUMAN; LIVER CANCER; LIVER TRANSPLANTATION; MULTIMODALITY CANCER THERAPY; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SWITZERLAND; TUMOR GROWTH; TUMOR VOLUME; VASCULAR ACCESS; CARCINOMA, HEPATOCELLULAR; EARLY DIAGNOSIS; LIVER NEOPLASMS; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; EARLY DETECTION OF CANCER; HUMANS; LIVER NEOPLASMS;

EID: 84903128131     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.68     Document Type: Conference Paper

References (19)

1. Budhu A, Roessler S, Zhao X et al. Integrated metabolite and gene expression profles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology 144 (5), 1066-1075 (2013).
2. Trinchet JC, Chaffaut C, Bourcier V et al. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH). Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3-and 6-month periodicities. Hepatology 54 (6), 1987-1997 (2011).
3. Claudon M, Dietrich CF, Choi BI et al.; World Federation for Ultrasound in Medicine; European Federation of Societies for Ultrasound. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver-update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med. Biol. 39 (2), 187-210 (2013).
4. Bolondi L, Cillo U, Colombo M et al.; Italian Association for the Study of the Liver (AISF); AISF Expert Panel; AISF Coordinating Committee. Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig. Liver Dis. 45(9), 712-723 (2013).
5. Lee JE, Jang JY, Jeong SW et al. Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan. World J. Gastroenterol. 18(23), 2979-2987 (2012).
6. Lim KC, Chow PK, Allen JC et al. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br. J. Surg. 99 (12), 1622-1629 (2012).
7. Cucchetti A, Piscaglia F, Cescon M et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J. Hepatol. 59(2), 300-307 (2013).
8. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63, 844-855 (2014).
9. Raoul JL, Sangro B, Forner A et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat. Rev. 37(3), 212-220 (2011).
10. Bolondi L, Burroughs A, Dufour JF et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassifcation to facilitate treatment decisions. Semin. Liver Dis. 32(4), 348-359 (2012).
11. Piscaglia F, Pecorelli A, Venerandi L et al. Clinical validation of a sub-staging proposal of patients with intermediate HCC (BCLC-B). J. Hepatol. 58, S45-S61 (2013).
12. Kadalayil L, Benini R, Pallan L et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann. Oncol. 24 (10), 2565-2570 (2013).
13. Sieghart W, Hucke F, Pinter M et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 57(6), 2261-2273 (2013).
14. Pawlik TM, Reyes DK, Cosgrove D et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J. Clin. Oncol. 29(30), 3960-3967 (2011).
15. Cabrera R, Pannu DS, Caridi J et al. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment. Pharmacol. Ther. 34(2), 205-213 (2011).
16. Lencioni R, Llovet JM, Han G et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. J. Clin. Oncol. 30 (Suppl. 4), Abstract LBA154 (2012).
17. Fornaro L, Vivaldi C, Caparello C et al. Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. Future Oncol. 10(2), 285-304 (2014).
18. Llovet JM, Decaens T, Raoul JL et al. Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the Phase 3 BRISK-PS study. J. Hepatol. 56, A1398 (2012).
19. Zhu AX, Kudo M, Assenat E et al. EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib. J. Clin. Oncol. 32 (Suppl. 3), Abstract 172 (2014).